Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

23 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Adiponectin in relation to malignancies: a review of existing basic research and clinical evidence.
Barb D, Williams CJ, Neuwirth AK, Mantzoros CS. Barb D, et al. Am J Clin Nutr. 2007 Sep;86(3):s858-66. doi: 10.1093/ajcn/86.3.858S. Am J Clin Nutr. 2007. PMID: 18265479 Review.
Circulating resistin levels are not associated with fat redistribution, insulin resistance, or metabolic profile in patients with the highly active antiretroviral therapy-induced metabolic syndrome.
Barb D, Wadhwa SG, Kratzsch J, Gavrila A, Chan JL, Williams CJ, Karchmer AW, Mantzoros CS. Barb D, et al. J Clin Endocrinol Metab. 2005 Sep;90(9):5324-8. doi: 10.1210/jc.2005-0742. Epub 2005 Jun 14. J Clin Endocrinol Metab. 2005. PMID: 15956078
Adiponectin: a link between obesity and cancer.
Barb D, Pazaitou-Panayiotou K, Mantzoros CS. Barb D, et al. Expert Opin Investig Drugs. 2006 Aug;15(8):917-31. doi: 10.1517/13543784.15.8.917. Expert Opin Investig Drugs. 2006. PMID: 16859394 Review.
Adiponectin signals in prostate cancer cells through Akt to activate the mammalian target of rapamycin pathway.
Barb D, Neuwirth A, Mantzoros CS, Balk SP. Barb D, et al. Endocr Relat Cancer. 2007 Dec;14(4):995-1005. doi: 10.1677/ERC-06-0091. Endocr Relat Cancer. 2007. PMID: 18045951
A phase II study of mifepristone (RU-486) in castration-resistant prostate cancer, with a correlative assessment of androgen-related hormones.
Taplin ME, Manola J, Oh WK, Kantoff PW, Bubley GJ, Smith M, Barb D, Mantzoros C, Gelmann EP, Balk SP. Taplin ME, et al. Among authors: barb d. BJU Int. 2008 May;101(9):1084-9. doi: 10.1111/j.1464-410X.2008.07509.x. BJU Int. 2008. PMID: 18399827 Clinical Trial.
Pharmacological management of nonalcoholic fatty liver disease.
Barb D, Portillo-Sanchez P, Cusi K. Barb D, et al. Metabolism. 2016 Aug;65(8):1183-95. doi: 10.1016/j.metabol.2016.04.004. Epub 2016 May 21. Metabolism. 2016. PMID: 27301803 Review.
Metabolic and histological implications of intrahepatic triglyceride content in nonalcoholic fatty liver disease.
Bril F, Barb D, Portillo-Sanchez P, Biernacki D, Lomonaco R, Suman A, Weber MH, Budd JT, Lupi ME, Cusi K. Bril F, et al. Among authors: barb d. Hepatology. 2017 Apr;65(4):1132-1144. doi: 10.1002/hep.28985. Epub 2017 Feb 25. Hepatology. 2017. PMID: 27981615
Translating What Works: A New Approach to Improve Diabetes Management.
Phillips LS, Barb D, Yong C, Tomolo AM, Jackson SL, Olson DE, Rhee MK, Duva IM, He Q, Long Q. Phillips LS, et al. Among authors: barb d. J Diabetes Sci Technol. 2015 Jul;9(4):857-64. doi: 10.1177/1932296815576000. Epub 2015 Mar 9. J Diabetes Sci Technol. 2015. PMID: 25759182 Free PMC article. Clinical Trial.
Effect of pioglitazone on bone mineral density in patients with nonalcoholic steatohepatitis: A 36-month clinical trial.
Portillo-Sanchez P, Bril F, Lomonaco R, Barb D, Orsak B, Bruder JM, Cusi K. Portillo-Sanchez P, et al. Among authors: barb d. J Diabetes. 2019 Mar;11(3):223-231. doi: 10.1111/1753-0407.12833. Epub 2018 Sep 3. J Diabetes. 2019. PMID: 30073778 Clinical Trial.
Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes.
Cusi K, Bril F, Barb D, Polidori D, Sha S, Ghosh A, Farrell K, Sunny NE, Kalavalapalli S, Pettus J, Ciaraldi TP, Mudaliar S, Henry RR. Cusi K, et al. Among authors: barb d. Diabetes Obes Metab. 2019 Apr;21(4):812-821. doi: 10.1111/dom.13584. Epub 2018 Dec 18. Diabetes Obes Metab. 2019. PMID: 30447037 Clinical Trial.
23 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback